{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:10:18Z","timestamp":1793419818574,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.tube.2018.04.008","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T21:39:42Z","timestamp":1525383582000},"page":"20-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"special_numbering":"C","title":["Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)"],"prefix":"10.1016","volume":"111","author":[{"given":"Yongge","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekaza","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinue","family":"Ohguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuhiro","family":"Yoshitake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Geiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hafkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2018.04.008_bib1","series-title":"Global tuberculosis report","year":"2017"},{"key":"10.1016\/j.tube.2018.04.008_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.tube.2018.04.008_bib3","series-title":"WHO treatment guidelines for drug-resistant tuberculosis (2016 update)","year":"2016"},{"key":"10.1016\/j.tube.2018.04.008_bib4","series-title":"A policy paper prepared for the first WHO global ministerial conference on ending tuberculosis in the sustainable development era: a multisectoral response","article-title":"Global investments in Tuberculosis research and development: past, present and future","year":"2017"},{"key":"10.1016\/j.tube.2018.04.008_bib5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMra1205429","article-title":"Tuberculosis, drug resistance, and the history of modern medicine","volume":"367","author":"Keshavjee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2018.04.008_bib6","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1016\/j.bmcl.2013.07.006","article-title":"A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis","volume":"23","author":"Dartois","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.tube.2018.04.008_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2174\/156802607780059727","article-title":"Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis","volume":"7","author":"Matsumoto","year":"2007","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.tube.2018.04.008_bib8","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1021\/jm060957y","article-title":"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles","volume":"49","author":"Sasaki","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2018.04.008_bib9","first-page":"137","volume":"vol. 68","author":"Tsubouchi","year":"2016"},{"key":"10.1016\/j.tube.2018.04.008_bib10","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.tube.2018.04.008_bib11","first-page":"631","article-title":"Nitroimidazoles 2,3-dihydro-6-nitroimidazole [2,1-b] oxazoles with antitubercular activity","volume":"24","author":"Nagarajan","year":"1989","journal-title":"Prog Drug Res"},{"key":"10.1016\/j.tube.2018.04.008_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.37.2.183","article-title":"In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis","volume":"37","author":"Ashtekar","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2018.04.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.09744","article-title":"The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis","volume":"5","author":"Patterson","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.tube.2018.04.008_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005971","article-title":"Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania","volume":"12","author":"Wyllie","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tube.2018.04.008_bib15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1128\/AAC.03823-14","article-title":"In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis","volume":"59","author":"Upton","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2018.04.008_bib16","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/AAC.03014-15","article-title":"MIC of delamanid (OPC-67683) against mycobacterium tuberculosis clinical isolates and a proposed critical concentration","volume":"60","author":"Stinson","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2018.04.008_bib17","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/jac\/dkw044","article-title":"Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC\u2122 MGIT\u2122 960 system","volume":"71","author":"Schena","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2018.04.008_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00900-17","article-title":"In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug -resistant tuberculosis from Beijing, China","author":"Pang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2018.04.008_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2471\/BLT.11.096644","article-title":"Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis","volume":"90","author":"\u00c4ngeby","year":"2012","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.tube.2018.04.008_bib20","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/IAI.64.6.2062-2069.1996","article-title":"An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence","volume":"64","author":"Wayne","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.tube.2018.04.008_bib21","first-page":"247","article-title":"In vitro model of hypoxically induced nonreplicating persistence of mycobacterium tuberculosis","volume":"54","author":"Wayne","year":"2001","journal-title":"Meth Mol Med"},{"key":"10.1016\/j.tube.2018.04.008_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02402-16","article-title":"Delamanid kills dormant mycobacteria in vitro and in a Guinea pig model of tuberculosis","volume":"61","author":"Chen","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2018.04.008_bib23","series-title":"Intersci conf antimicrob agents chemother","article-title":"Characteristic antimycobacterial spectra of the novel anti-TB drug candidates OPC-67683 and PA-824","author":"Doi","year":"2006"},{"key":"10.1016\/j.tube.2018.04.008_bib24","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1183\/13993003.01420-2016","article-title":"Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare?","volume":"48","author":"Krieger","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2018.04.008_bib25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1124\/dmd.115.064527","article-title":"Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo","volume":"43","author":"Sasahara","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.tube.2018.04.008_bib26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/dmd.115.064550","article-title":"Metabolic mechanism of delamanid, a new anti-tuberculosis drug, in human plasma","volume":"43","author":"Shimokawa","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.tube.2018.04.008_bib27","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1128\/AAC.01094-16","article-title":"Antitubercular agent delamanid and metabolites as substrates and inhibitors of ABC and solute Carrier transporters","volume":"60","author":"Sasabe","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2018.04.008_bib28","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1248\/bpb.b14-00311","article-title":"Delamanid does not inhibit or induce cytochrome P450 enzymes in vitro","volume":"37","author":"Shimokawa","year":"2014","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.tube.2018.04.008_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/bdd.2064","article-title":"Absorption, distribution and excretion of the anti-tuberculosis drug delamanid in rats: extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis","author":"Shibata","year":"2017","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.tube.2018.04.008_bib30","series-title":"Assessment report","first-page":"44","author":"European Medicines Agency","year":"2013"},{"key":"10.1016\/j.tube.2018.04.008_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yrtph.2016.12.002","article-title":"Delamanid is not metabolized by Salmonella or human nitroreductases\u202f: a possible mechanism for the lack of mutagenicity","volume":"84","author":"Hanaki","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.tube.2018.04.008_bib32","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1038\/s41598-017-09177-2","article-title":"NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans","volume":"7","author":"Gengenbacher","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.tube.2018.04.008_bib33","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1046\/j.1365-2958.1998.01026.x","article-title":"The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis","volume":"29","author":"Yuan","year":"1998","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.tube.2018.04.008_bib34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tube.2017.12.006","article-title":"Mechanisms of resistance to delamanid, a drug for mycobacterium tuberculosis","volume":"108","author":"Fujiwara","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2018.04.008_bib35","first-page":"1","article-title":"Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis","volume":"12","author":"Operario","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2018.04.008_bib36","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis","volume":"373","author":"Bloemberg","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2018.04.008_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1164\/rccm.201502-0372LE","article-title":"Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee","volume":"193","author":"Hoffmann","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2018.04.008_bib38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1073\/pnas.0508392103","article-title":"Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis","volume":"103","author":"Manjunatha","year":"2006","journal-title":"Proc Natl Acad Sci U. S. A."},{"key":"10.1016\/j.tube.2018.04.008_bib39","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1128\/AAC.00308-15","article-title":"Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis","volume":"59","author":"Haver","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2018.04.008_bib40","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4155\/fmc.11.90","article-title":"Nitroimidazoles for the treatment of TB: past, present and future","volume":"3","author":"Mukherjee","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1016\/j.tube.2018.04.008_bib41","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5588\/ijtld.10.0616","article-title":"Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients","volume":"15","author":"Diacon","year":"2011","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.tube.2018.04.008_bib42","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2018.04.008_bib43","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1128\/AAC.00509-16","article-title":"Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects","volume":"60","author":"Mallikaarjun","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2018.04.008_bib44","first-page":"1","volume":"vol. 44","author":"European Medicines Agency","year":"2016"},{"key":"10.1016\/j.tube.2018.04.008_bib45","series-title":"Guidance for industry: pulmonary tuberculosis: developing drugs for treatment","author":"FDA","year":"2013"},{"key":"10.1016\/j.tube.2018.04.008_bib46","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1183\/09031936.00125812","article-title":"Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis","volume":"41","author":"Skripconoka","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2018.04.008_bib47","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1183\/09031936.00176314","article-title":"Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid","volume":"45","author":"Wells","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2018.04.008_bib48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1415332","article-title":"Delamanid for extensively drug-resistant tuberculosis","volume":"373","author":"Gupta","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2018.04.008_bib49","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.5588\/ijtld.15.0541","article-title":"Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis","volume":"19","author":"Gupta","year":"2015","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.tube.2018.04.008_bib50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1586\/14787210.2015.1011127","article-title":"Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis","volume":"13","author":"Sotgiu","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.tube.2018.04.008_bib51","series-title":"Intersci. Conf. Antimicrob. Agents chemother., San Diego, CA. USA","article-title":"Pharmacokinetics and safety of selamanid in children ages 6-17 years with MDR-TB","author":"Hafkin","year":"2015"},{"key":"10.1016\/j.tube.2018.04.008_bib52","series-title":"46th union world conf. Lung heal., Cape Town, South Africa","article-title":"Long-term safety, tolerability, and pharmacokinetics of delamanid in children ages 12\u201317","author":"Hafkin","year":"2015"},{"key":"10.1016\/j.tube.2018.04.008_bib53","series-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance","first-page":"1","year":"2016"},{"key":"10.1016\/j.tube.2018.04.008_bib54","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1183\/13993003.01105-2017","article-title":"Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens","volume":"50","author":"Kuksa","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2018.04.008_bib55","first-page":"4","article-title":"Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea","author":"Mok","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2018.04.008_bib56","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00311-2017","article-title":"Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use","volume":"50","author":"Hafkin","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2018.04.008_bib57","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1183\/09031936.00060414","article-title":"ERS\/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use","volume":"44","author":"Esposito","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2018.04.008_bib58","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3201\/eid2310.170468","article-title":"Six-month response to delamanid treatment in MDR TB patients","volume":"23","author":"Hewison","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tube.2018.04.008_bib59","series-title":"Summary of product characteristics for delamanid","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.tube.2018.04.008_bib60","series-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance","first-page":"1","year":"2014"},{"key":"10.1016\/j.tube.2018.04.008_bib61","series-title":"WHO position statement on the use of delamanid for multidrug-resistant tuberculosis","year":"2018"},{"key":"10.1016\/j.tube.2018.04.008_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0015803","article-title":"Metabolic engineering of cofactor F420 production in mycobacterium smegmatis","volume":"5","author":"Bashiri","year":"2010","journal-title":"PLoS One"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979218300489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979218300489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T14:51:05Z","timestamp":1604242265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979218300489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":62,"alternative-id":["S1472979218300489"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2018.04.008","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2018.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}